Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 676 to 700 of 903

TitleReference numberPublishedLast updated
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancerTA424
Ticagrelor for preventing atherothrombotic events after myocardial infarctionTA420
Dapagliflozin in combination therapy for treating type 2 diabetesTA288
Nivolumab for previously treated advanced renal cell carcinomaTA417
Dapagliflozin in triple therapy for treating type 2 diabetesTA418
Apremilast for treating moderate to severe plaque psoriasisTA419
Elbasvir–grazoprevir for treating chronic hepatitis CTA413
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanomaTA414
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitorTA415
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerTA406
Secukinumab for treating active ankylosing spondylitisTA407
Pegaspargase for treating acute lymphoblastic leukaemiaTA408
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusionTA409
Talimogene laherparepvec for treating unresectable metastatic melanomaTA410
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancerTA411
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastasesTA412
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatinTA402
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancerTA403
Degarelix for treating advanced hormone-dependent prostate cancerTA404
Trifluridine–tipiracil for previously treated metastatic colorectal cancerTA405
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxelTA391
Bosutinib for previously treated chronic myeloid leukaemiaTA401
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimenTA259
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blastsTA399
Nivolumab in combination with ipilimumab for treating advanced melanomaTA400

Results per page

  1. 10
  2. 25
  3. 50
  4. All